June 2, 2009
This quote sums up this article on statins:
“The results of our study indicate that simvastatin has in fact, a slightly deleterious effect on myelin under non-pathological conditions,” adds Dr. Miron. “During remyelination, there is a decrease not only in myelin production but also in oligodendrocyte number as a result of simvastatin treatment. The findings also suggest that simvastatin inhibits CNS remyelination by blocking oligodendrocyte progenitor cell differentiation or maturation into myelinating oligodendrocytes.”
It wasn't that long ago that we were looking at statins as a therapy for MS. Seems like there's a bit of understanding that needs to take place before we continue with that idea.

